Transaction details and immediate market reaction
On March 31, 2026, Lynx1 Capital Management L.P. acquired 520 shares of Korro Bio, Inc. (NASDAQ: KRRO) common stock in an open-market transaction. The shares were purchased at $10.60 each, producing a total transaction value of $5,512. Since that purchase, the Korro Bio share price has moved to $13.85, a rise that represents approximately a 30% gain relative to the purchase price.
Positioning and ownership structure
Following the March 31 purchase, Lynx1 Capital Management L.P. holds 1,538,296 shares of Korro Bio. Those shares are held directly by Lynx1 Master Fund LP, with Lynx1 Capital Management LP serving as the investment manager. Weston Nichols, the sole member of Lynx1 Capital Management GP LLC, which is the general partner of the investment manager, disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest. Lynx1 is reported as a ten percent owner of Korro Bio.
Recent corporate developments and analyst activity
Korro Bio has been active on the financing and analyst fronts. The company secured $85 million in private equity financing, led by Venrock Healthcare Capital Partners, with participation from ADAR1 Capital Management and New Enterprise Associates. In parallel with the capital raise, several sell-side firms updated their views on the stock.
Raymond James upgraded Korro Bio from Market Perform to Outperform, citing a favorable view of the company’s focus on hyperammonemia indications. Clear Street raised its rating to Buy from Hold and increased its price target to $18.00, pointing to the potential of the KRRO-121 program. Cantor Fitzgerald reiterated an Overweight rating and lifted its price target to $22.00, reflecting confidence in the company’s urea cycle disorder clinical development program.
Performance and market metrics
Per InvestingPro data, KRRO returned 15.95% over the last week and has produced a 57.93% year-to-date gain. InvestingPro also notes the stock exhibits elevated volatility, with a reported beta of 2.54. The data source references the availability of 12 additional ProTips for investors seeking further detail on KRRO’s investment profile.
Contextual note
The sequence of an insider-related purchase, a sizable private equity financing, and multiple analyst upgrades has coincided with notable upward price movement for Korro Bio. The items above are presented as reported facts, including the precise transaction terms, the company’s financing and analyst actions, and the market performance and volatility metrics attributed to InvestingPro.